Clinical Trials
81 trialsA First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
Blueprint Medicines Corporation
DUAL-NK-PDAC
Beijing Biotech
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
National Cancer Institute (NCI)
CERTIS1
AstraZeneca
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
National Institutes of Health Clinical Center (CC)
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
Bristol-Myers Squibb
EVEREST-2
A2 Biotherapeutics Inc.
Exploratory Clinical Study of HRS-4642 Combined With Adebrelimab in the Treatment of Advanced Pancreatic Ductal Adenocarcinoma
Fudan University
A Study of JMT203 in Patients With Cancer Cachexia
Shanghai JMT-Bio Inc.
PANCOSIL
Amsterdam UMC, location VUmc
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
M.D. Anderson Cancer Center
NALIRIFOX+Adebrelimab+PULSAR for Advanced Pancreatic Cancer
West China Hospital
BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours
Bold Therapeutics, Inc.
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Revolution Medicines, Inc.
A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer
Cancer Research UK
Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer
M.D. Anderson Cancer Center
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
ModeX Therapeutics, An OPKO Health Company
TEADCO
Orion Corporation, Orion Pharma
XER-001
Xerient Pharma
Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma
Roswell Park Cancer Institute
Adapted Guided Stereotactic Body Radiotherapy Combined With Chemotherapy and Enhancement of Novel Drug Ivonescimab for Pancreatic Cancer (ASCEND)
Shandong Cancer Hospital and Institute
A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
Tyligand Pharmaceuticals (Suzhou) Limited
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Revolution Medicines, Inc.
PANGEA
UNC Lineberger Comprehensive Cancer Center
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Verastem, Inc.
Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca
Virginia Commonwealth University
Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments
Evopoint Biosciences Inc.
KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors
National Cancer Institute (NCI)
SELECT-2CAR
Beijing Biotech
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
National Institutes of Health Clinical Center (CC)
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Revolution Medicines, Inc.
PROSPER
Frontier Medicines Corporation
DUAL-NK-PDAC
Beijing Biotech
ADVICE
Filamon LTD
Panc 002
University of Virginia
Carolyn-USA
Engeneic Pty Limited
Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC
Mayo Clinic
Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor
Sichuan Enray Pharmaceutical Sciences Company
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
Arvinas Inc.
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Tasca Therapeutics
EBNK-ST-001
Essen Biotech
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
MBrace Therapeutics
Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.
Auricula Biosciences Inc.
LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study
Zhejiang Provincial People's Hospital
A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration
Jacobio Pharmaceuticals Co., Ltd.
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
Lumicell, Inc.
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
Jacobio Pharmaceuticals Co., Ltd.
Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer
Changhai Hospital
Phase I/II Study: Allogeneic NK-cell Therapy With Chemotherapy for Post-Surgery PDA or Cholangiocarcinoma Patients
Medigen Biotechnology Corporation